Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 90
Summary
- Conditions
- AML Arising After Exposure to Genotoxic Injury
- AML Arising From Antecedent Hematologic Disorder (AHD)
- AML Arising From Myelodysplastic Syndrome (MDS)
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Untreated AML
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02632708
- Collaborators
- Celgene Corporation
- Investigators
- Study Director: Clinical Development Agios Pharmaceuticals, Inc.